One of the most potent compounds identified to date in the OSDD malaria project, the near-neighbour analog OSM-S-35 (ZYH3) was subjected to the hERG assay along with one of the original TCAMS GSK compounds which in this project has the tag OSM-S-5.

Raw data are here, plus spreadsheet here.

It is common in drug discovery to have a highly potent hit that has to be optimised to remove undesirable characteristics such as poor oral bioavailablity, metabolic stability or toxicity. In our case, we have a number of highly potent compounds that have quite a high LogP, which is considered a warning sign for both a promiscousity (i.e. binding to many compound targets in vitro) as well as poor oral bioavailabilty (as it breaks the Lipinski Rule of 5).
 

More fantastic work from Iain Wallace of ChEMBL, below. These are maps of active antimalarials and predicted targets, expressed as similarity maps, i.e. with an extra level of analysis added on top. This provides a very intuitive way of walking through related compounds to compare structures. How best do we use this kind of analysis - as a target guide, or as a "prediction of what to make next" guide?